The trials will enroll approximately 30,000 adult volunteers at 80 sites in the US to evaluate if the candidate vaccine, known as AZD1222, can prevent symptomatic Covid-19
The trials will enroll approximately 30,000 adult volunteers at 80 sites in the US to evaluate if the candidate vaccine, known as AZD1222, can prevent symptomatic Covid-19